20 Jul 2018 | 8:22 PM
Research Report

Equity Research Report: Master Pick-Ipca Lab

The domestic business has been a key growth driver for IPCA as the company changed focus from the low margin anti-malarial segment to focus on higher margin chronic/lifestyle diseases.
17 Jul 2015 | 06:00 PM

IPCALAB saw gradually decline from the top, after breakdown from the pattern and tested its major support area of 200 EMA on weekly chart around 600. It has been hovering in a broader range of 600-760 for last five months and formed a fresh buying pivot. We expect resumption of uptrend soon so participations’ can initiate fresh long positions in given range of 700-710 with close below stop loss of 670 for the target of 790.